BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 3, 2015
View Archived Issues
Alios Biopharma starts first-in-human study of HCV polymerase inhibitor AL-704
Read More
Novavax reports data from phase II trial of quadrivalent seasonal influenza vaccine
Read More
arGEN-X and University of Bern to develop ARGX-110-based combination therapies
Read More
University of Sydney to study Cymerus stem cells in heart disease models
Read More
Heptares to use MorphoSys antibody discovery technology against GPCR target
Read More
D-Pharm reports results from pilot trial of DP-b99 in acute pancreatitis
Read More
Filgotinib meets key efficacy endpoints in phase IIb DARWIN 1 study
Read More
Eisai and Halozyme sign collaboration agreement to investigate eribulin and PEGPH-20
Read More
Beijing Normal University patents technetium complexes for imaging
Read More
Coferon discloses Bcr-Abl tyrosine-kinase ligands
Read More
FDA accepts IND for EDO-S101 in patients with hematologic malignancies and solid tumors
Read More
KannaLife Sciences describes neuroprotectants
Read More
Aurigene Discovery Technologies divulges IRAK-4 inhibitors
Read More
KT&G Life Sciences develops NQO1 modulators
Read More
Alios Biopharma starts phase I drug interaction study for AL-335
Read More
AstraZeneca and Isis Pharmaceuticals form second antisense therapy collaboration
Read More
Sanofi profiles pipeline progress of second quarter 2015
Read More
Novel apelin receptor agonist shows promise as vasodilator
Read More
Perjeta regimen approved in E.U. for use before surgery in early-stage breast cancer
Read More
CTLA4-targeted therapies show promise for the treatment of LRBA deficiency
Read More
Allergan's AGN-223575 enters phase II study in dry eye
Read More
Biocad initiates phase I trial comparing adalimumab biosimilar to Humira
Read More
Anti-GD2 antibody enters phase II trial in osteosarcoma
Read More
TiGenix acquires Coretherapix
Read More
ORAI1 inhibitors show potential for the treatment of pancreatitis
Read More